Document Detail

Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats.
MedLine Citation:
PMID:  21182938     Owner:  NLM     Status:  In-Data-Review    
Atorvastatin is a selective HMG-CoA reductase competitive inhibitor, used for the treatment of hyperlipidaemia. It is metabolized by CYP 3A4 and 3A5 isoenzymes in liver. It also has moderate inhibition on metabolizing enzymes like CYP 2C9, 2D6 and 3A4. Hence there is more possibility of atorvastatin for inhibition of metabolism of glyburide, by both CYP 2C9 and 3A4. We have studied the effects of atorvastatin on the pharmacodynamics and pharmacokinetics of glyburide in experimental diabetic rats. Atorvastatin (20mg/kg p.o.) was given to alloxan-induced diabetic rats for 7 consecutive days followed by glyburide (10mg/kg p.o.). In the rats co-treated with atorvastatin and glyburide, fasting plasma glucose concentration (60.69±5.70%) was further reduced, markedly as compared with glyburide-treated animals. In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats. The results of this study revealed that atorvastatin led to the PK/PD changes have been due to glyburide increased bioavailability, decrease volume of distribution, and/or decrease total clearance may be due to the inhibition of cytochrome P450 metobolic system.
Prasad Neerati; Jyothsna Gade
Related Documents :
22851928 - Exploiting the nephrotoxic effects of venom from the sea anemone, phyllodiscus semoni, ...
10388268 - Partial cross-resistance between strongyloides venezuelensis and nippostrongylus brasil...
9628468 - Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis b...
10815758 - Mechanism of antinephritic effect of proteinase inhibitors in experimental anti-gbm glo...
6426988 - Age and sex difference in serum and pituitary thyrotropin concentrations in the rat: in...
3068708 - Neuropeptide y and vasoactive intestinal peptide coexist in rat thyroid nerve fibers em...
Publication Detail:
Type:  Journal Article     Date:  2010-12-21
Journal Detail:
Title:  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences     Volume:  42     ISSN:  1879-0720     ISO Abbreviation:  Eur J Pharm Sci     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9317982     Medline TA:  Eur J Pharm Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  285-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier B.V. All rights reserved.
DMPK & Clinical Pharmacology Division, Department of Pharmacology, University College of Pharm Sciences, Kakatiya University, Warangal 506009, AP, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antimicrobial activity of ruthenium-based intercalators.
Next Document:  Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery.